Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short-term Investments (2016 - 2025)

Amicus Therapeutics' Short-term Investments history spans 16 years, with the latest figure at $79.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 119.72% year-over-year to $79.5 million, compared with a TTM value of $79.5 million through Dec 2025, up 119.72%, and an annual FY2025 reading of $79.5 million, up 119.72% over the prior year.
  • Short-term Investments for Q4 2025 was $79.5 million at Amicus Therapeutics, up from $73.3 million in the prior quarter.
  • The five-year high for Short-term Investments was $237.3 million in Q4 2021, with the low at $16.1 million in Q3 2024.
  • Average Short-term Investments over 5 years is $102.1 million, with a median of $75.2 million recorded in 2022.
  • Year-over-year, Short-term Investments tumbled 77.98% in 2023 and then soared 354.93% in 2025.
  • Tracing FOLD's Short-term Investments over 5 years: stood at $237.3 million in 2021, then tumbled by 38.99% to $144.8 million in 2022, then plummeted by 72.92% to $39.2 million in 2023, then fell by 7.68% to $36.2 million in 2024, then skyrocketed by 119.72% to $79.5 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Short-term Investments are $79.5 million (Q4 2025), $73.3 million (Q3 2025), and $72.3 million (Q2 2025).